BIO-FD&C CO.,LTD.
251120KOSDAQPharmaceuticals
BIO-FD&C CO.,LTD. (251120, KOSDAQ) reported KRW 19bn revenue in 2025.
Reported financials
Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.
| Year | Revenue | Operating profit | Net profit | Assets | Equity | Basis |
|---|---|---|---|---|---|---|
| 2023 | 16 | 5 | 6 | 63 | 59 | Separate |
| 2024 | 16 | 5 | 5 | 67 | 63 | Separate |
| 2025 | 19 | 6 | 7 | 73 | 70 | Separate |
Ratios, year by year
Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.
| Year | Operating margin | Net margin | Equity / assets | Return on equity |
|---|---|---|---|---|
| 2023 | 32.3% | 35.8% | 93.3% | 9.5% |
| 2024 | 30.2% | 28% | 93.8% | 7.1% |
| 2025 | 32.6% | 34.8% | 95% | 9.6% |
Revenue moved 23% between 2023 and 2025.
These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.
Market size
| Market capitalisation | KRW 74bn |
|---|---|
| Close price | KRW 8,550 |
| Listed shares | 8,695,700 |
| Price as of | 20260909 |
Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.
Workforce — a side measure, not the main one
| Employees (2025) | 78 |
|---|---|
| Women | 42 (53.8%) |
| Average tenure | 4.9 years |
| Annual pay, men | KRW 61,785,722 |
| Annual pay, women | KRW 50,277,690 |
| Pay ratio, women to men | 81.4% |
Other companies in Pharmaceuticals
181 listed companies file under this classification. Showing 12.